The current P/E of 48.5 and EV/EBITDA of 47.3 are steep relative to the peer group, where most companies are loss-making and trade on asset value. The forward EV/EBITDA of 20.9 suggests the market is pricing in a substantial EBITDA increase, likely tied to the HALEU production ramp. However, the PEG of 1.03 indicates that the growth rate implied by the forward multiple is roughly in line with the earnings growth forecast, but given the lumpy revenue history, investors should question the reliability of that growth estimate.

The extreme variability in margins—gross margin from -5.7% to 45.0% and operating margin from -22.2% to 28.0%—indicates that quarterly profitability is heavily influenced by the timing of deliveries and cost recognition. The 2026Q2 net margin of 9.5% on an operating margin of 5.9% suggests non-operating gains or tax benefits, as noted in prior analysis. Investors should focus on normalized margins over a full cycle, which appear to be in the mid-teens to low-twenties, rather than any single quarter's figure.

The ROIC figures are highly volatile, with a 195.4% peak in 2024Q2 and a -15.4% trough in 2024Q3, reflecting the lumpy nature of uranium deliveries and the timing of investments. The recent 6.5% ROIC in 2026Q2 is more indicative of the current capital intensity, as the company invests heavily in HALEU production. Over the long term, the company's ability to generate returns above its cost of capital will depend on the successful commercialization of HALEU, which is not yet reflected in the data.

The cash conversion cycle has been extremely volatile, ranging from 131 days in 2024Q2 to 692 days in 2025Q1, driven by swings in DIO (inventory days) which reached 631 days in 2026Q1. This suggests that inventory is being accumulated, possibly for future HALEU production, but it also ties up significant capital. Asset turnover has declined to 0.07 in 2026Q2, as the balance sheet has expanded with cash and PP&E, indicating that the company is becoming more asset-heavy, which may pressure returns if revenue does not scale accordingly.

The leverage metrics have improved significantly from the 2025Q3 peak, with D/E dropping to 1.39 and interest coverage rising to 6.14 in 2026Q2. However, the D/EBITDA ratio of 88.5 in 2026Q2 is extremely high, indicating that EBITDA is depressed relative to the debt load, likely due to the lumpy revenue and heavy investment phase. The company's ability to service its debt will depend on generating consistent EBITDA from HALEU sales, which is not yet evident in the data.

The current ratio of 5.39 and quick ratio of 4.52 in 2026Q2 indicate a strong liquidity position, largely due to the $1.9B cash balance. However, the negative free cash flow of -$111.5M in 2026Q2, driven by heavy capex and working capital outflows, suggests that the cash pile may be drawn down if the investment phase continues. The high inventory levels (DIO of 257 days) could become a liquidity risk if uranium prices decline or if the inventory becomes obsolete, but the current cash buffer provides a significant cushion.